scholarly journals Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report

2018 ◽  
Vol Volume 11 ◽  
pp. 8705-8710 ◽  
Author(s):  
Yan Gao ◽  
Aihong Zheng ◽  
Xiuming Zhu ◽  
Jia Song ◽  
Qian Xue
Keyword(s):  
Case Report ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
Clinical Benefit ◽  
Squamous Cell Lung Carcinoma ◽  
Cell Lung Carcinoma ◽  
Carcinoma Patient

scholarly journals Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes

2021 ◽  
Vol 11 ◽  
Author(s):  
Liping Hao ◽  
Ying Hu ◽  
Jianjun Hu ◽  
Yang Liu ◽  
Beibei Mao ◽  
...  
Keyword(s):  
T Cells ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
Serum Levels ◽  
Squamous Cell Lung Carcinoma ◽  
Tumor Biopsy ◽  
Adjuvant Immunochemotherapy ◽  
Cell Lung Carcinoma ◽  
Carcinoma Patient ◽  
Anastomosis Leakage

Clinical trials indicated that PD-1/PD-L1 inhibitors significantly improve the survival rate of patients with advanced non-small cell lung cancer (NSCLC) and induce immune-related adverse events (irAEs). Thus, the molecular and immune characteristics during PD-1/PD-L1 inhibitor therapy are worth investigating further. We report the case of a 62-year-old male patient diagnosed with stage IIIA squamous cell lung carcinoma (SQCC) who responded to neoadjuvant and adjuvant nivolumab combined chemotherapy but died from anastomosis leakage or/and irAEs. In the pretreatment tumor biopsy, PD-L1 expression was negative and a few T cells, NK cells, and macrophages had infiltrated the tumor. Wild-type EGFR/STK11, mutant TP53, microsatellite stability, and low tumor mutational burden were also found at baseline. After neoadjuvant immunochemotherapy, the tumor was significantly reduced, PD-L1 expression levels were increased by 50%, and more CD8+ and CD8+ PD-1+ T cells had infiltrated the resected tumor tissue. Immune-related lung injury occurred during adjuvant immunochemotherapy, and serum levels of C-reactive protein, IL-13, IL-4, eotaxin, VEGF-A, IL-8, and IFN-gamma were increased. This case demonstrates a squamous cell lung carcinoma patient who responded to neoadjuvant immunochemotherapy that reshaped the tumor immune environment from “cold” to “hot.” Unfortunately, the patient eventually died from anastomosis leakage or/and irAEs during adjuvant immunochemotherapy.

scholarly journals Acute cholangitis due to pancreatic metastasis from squamous cell lung carcinoma: a case report and review of literature

Cases Journal ◽  
2009 ◽  
Vol 2 (1) ◽  
Author(s):  
Maria A Kyriazi ◽  
Chrisostomos Sofoudis ◽  
Maria Katsouri ◽  
Theocharis Kappos ◽  
Christos Zafeiris ◽  
...  
Keyword(s):  
Case Report ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
Acute Cholangitis ◽  
Pancreatic Metastasis ◽  
Squamous Cell Lung Carcinoma ◽  
Review Of Literature ◽  
Cell Lung Carcinoma

scholarly journals Squamous Cell Lung Carcinoma Presenting as Melena: A Case Report and Review of the Literature

Rare Tumors ◽  
2017 ◽  
Vol 9 (3) ◽  
pp. 85-88 ◽  
Author(s):  
Ibrahim Azar ◽  
Efstratios Koutroumpakis ◽  
Raina Patel ◽  
Syed Mehdi
Keyword(s):  
Case Report ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
Squamous Cell Lung Carcinoma ◽  
Review Of The Literature ◽  
Cell Lung Carcinoma

scholarly journals Nodular‐type central squamous cell lung carcinoma cured by intraluminal bronchoscopic treatment: A case report

2021 ◽  
Author(s):  
Hikaru Aoki ◽  
Keigo Uchimura ◽  
Tatsuya Imabayashi ◽  
Yuji Matsumoto ◽  
Masahiro Higashiyama ◽  
...  
Keyword(s):  
Case Report ◽  
Squamous Cell ◽  
Lung Carcinoma ◽  
Squamous Cell Lung Carcinoma ◽  
Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document